Equasens Société anonyme (EQS) H2 2025 earnings summary

Executive summary

• FY 2025 revenue reached €236.5 million, up 9.1% year-over-year, driven by innovative healthcare solutions and international expansion.

• Annual Recurring Revenue (ARR) rose 8.8% to €108.0 million, reflecting a robust recurring business model.

• EBITDA increased 9.1% to €66.7 million, with net profit up 8.8% to €41.1 million, supporting a proposed €1.40 dividend per share.

• Continued M&A activity, notably the acquisition of Erevo, and technology investments strengthened the portfolio.

Financial highlights

• Net cash position improved to €83.6 million at year-end 2025, up €4.1 million.

• Cash flow from operations after interest and tax rose by €9.0 million to €56.7 million.

• Operating capital expenditure totaled €12.1 million, with €10.6 million allocated to R&D.

• Financial investments reached €24.1 million, mainly for external growth, financed by bank debt.

Outlook and guidance

• Focus remains on technological innovation, interoperability, and AI integration within SaaS healthcare solutions.

• Plans to develop agentic AI layers for automation and enhanced decision support in 2026.

• Aims to further strengthen leadership in the French and European digital health market.